Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary

References

• Jamieson S, Fuller PJ. Molecular pathogenesis of granulosa cell tumors of the ovary. Endocr Rev. 2012;33:109–44.
   PubMed Web of Science ®Google Scholar
• Bryk S, Pukkala E, Martinsen JI, Unkila-Kallio L, Tryggvadottir L, Sparen P, et al. Incidence and occupational variation of ovarian granulosa cell tumours in Finland, Iceland, Norway and Sweden during 1953–2012: a longitudinal cohort study. BJOG. 2017;124:143--49.
   PubMed Web of Science ®Google Scholar
• Young RH, Dickersin GR, Scully RE. Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases. Am J Surg Pathol. 1984;8:575–96.
   PubMed Web of Science ®Google Scholar
• Bryk S, Farkkila A, Butzow R, Leminen A, Heikinheimo M, Anttonen M, et al. Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience. Int J Gynecol Cancer. 2015;25:33–41.
   PubMed Web of Science ®Google Scholar
• Mangili G, Ottolina J, Gadducci A, Giorda G, Breda E, Savarese A, et al. Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary. Br J Cancer. 2013;109:29–34.
   PubMed Web of Science ®Google Scholar
• Kim JA, Chun YK, Moon MH, Lee YH, Cho HC, Lee MS, et al. High-resolution sonographic findings of ovarian granulosa cell tumors: correlation with pathologic findings. J Ultrasound Med. 2010;29:187–93.
   PubMed Web of Science ®Google Scholar
• van Meurs HS, Bleeker MC, van der Velden J, Overbeek LI, Kenter GG, Buist MR. The incidence of endometrial hyperplasia and cancer in 1031 patients with a granulosa cell tumor of the ovary: long-term follow-up in a population-based cohort study. Int J Gynecol Cancer. 2013;23:1417–22.
   PubMed Web of Science ®Google Scholar
• Sun HD, Lin H, Jao MS, Wang KL, Liou WS, Hung YC, et al. A long-term follow-up study of 176 cases with adult-type ovarian granulosa cell tumors. Gynecol Oncol. 2012;124:244–9.
   PubMed Web of Science ®Google Scholar
• Wilson MK, Fong P, Mesnage S, Chrystal K, Shelling A, Payne K, et al. Stage I granulosa cell tumours: a management conundrum? Results of long-term follow up. Gynecol Oncol. 2015;138:285–91.
   PubMed Web of Science ®Google Scholar
• Prat J. Oncology FCoG. FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26:87–9.
   PubMed Web of Science ®Google Scholar
• McConechy MK, Farkkila A, Horlings HM, Talhouk A, Unkila-Kallio L, van Meurs HS, et al. Molecularly defined adult granulosa cell tumor of the ovary: the clinical phenotype. J Natl Cancer Inst. 2016;108:djw134.
   PubMedGoogle Scholar
• Cronje HS, Niemand I, Bam RH, Woodruff JD. Review of the granulosa-theca cell tumors from the Emil Novak ovarian tumor registry. Am J Obstet Gynecol. 1999;180:323–7.
   PubMed Web of Science ®Google Scholar
• Lee IH, Choi CH, Hong DG, Song JY, Kim YJ, Kim KT, et al. Clinicopathologic characteristics of granulosa cell tumors of the ovary: a multicenter retrospective study. J Gynecol Oncol. 2011;22:188–95.
   PubMed Web of Science ®Google Scholar
• East N, Alobaid A, Goffin F, Ouallouche K, Gauthier P. Granulosa cell tumour: a recurrence 40 years after initial diagnosis. J Obstet Gynaecol Can. 2005;27:363–4.
   PubMedGoogle Scholar
• Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK. Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013;19:6389–97.
   PubMed Web of Science ®Google Scholar
• Lee YK, Park NH, Kim JW, Song YS, Kang SB, Lee HP. Characteristics of recurrence in adult-type granulosa cell tumor. Int J Gynecol Cancer. 2008;18:642–7.
   PubMed Web of Science ®Google Scholar
• Bryk S, Färkkilä A, Butzow R, Leminen A, Tapper J, Heikinheimo M, et al. Characteristics and outcomes of recurrence in the molecularly defined adult-type ovarian granulosa cell tumor. Gynecol Oncol. 2016;143:571--77.
   PubMed Web of Science ®Google Scholar
• Bjorkholm E, Silfversward C. Prognostic factors in granulosa-cell tumors. Gynecol Oncol. 1981;11:261–74.
   PubMed Web of Science ®Google Scholar
• Auranen A, Sundstrom J, Ijas J, Grenman S. Prognostic factors of ovarian granulosa cell tumor: a study of 35 patients and review of the literature. Int J Gynecol Cancer. 2007;17:1011–8.
   PubMed Web of Science ®Google Scholar
• Nosov V, Silva I, Tavassoli F, Adamyan L, Farias-Eisner R, Schwartz PE. Predictors of recurrence of ovarian granulosa cell tumors. Int J Gynecol Cancer. 2009;19:628–33.
   PubMed Web of Science ®Google Scholar
• Miller BE, Barron BA, Dockter ME, Delmore JE, Silva EG, Gershenson DM. Parameters of differentiation and proliferation in adult granulosa cell tumors of the ovary. Cancer Detect Prev. 2001;25:48–54.
   PubMedGoogle Scholar
• Farkkila A, Andersson N, Butzow R, Leminen A, Heikinheimo M, Anttonen M, et al. HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study. Cancer Med. 2014;3:526–36.
   PubMed Web of Science ®Google Scholar
• Miller K, McCluggage WG. Prognostic factors in ovarian adult granulosa cell tumour. J Clin Pathol. 2008;61:881–4.
   PubMed Web of Science ®Google Scholar
• Shah SP, Kobel M, Senz J, Morin RD, Clarke BA, Wiegand KC, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009;360:2719–29.
   PubMed Web of Science ®Google Scholar
• Kim T, Sung CO, Song SY, Bae DS, Choi YL. FOXL2 mutation in granulosa-cell tumours of the ovary. Histopathology. 2010;56:408–10.
   PubMed Web of Science ®Google Scholar
• Jamieson S, Butzow R, Andersson N, Alexiadis M, Unkila-Kallio L, Heikinheimo M, et al. The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Mod Pathol. 2010;23:1477–85.
   PubMed Web of Science ®Google Scholar
• Al-Agha OM, Huwait HF, Chow C, Yang W, Senz J, Kalloger SE, et al. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol. 2011;35:484–94.
   PubMed Web of Science ®Google Scholar
• Gershon R, Aviel-Ronen S, Korach J, Daniel-Carmi V, Avivi C, Bar-Ilan D, et al. FOXL2 C402G mutation detection using MALDI-TOF-MS in DNA extracted from Israeli granulosa cell tumors. Gynecol Oncol. 2011;122:580–4.
   PubMed Web of Science ®Google Scholar
• Schrader KA, Gorbatcheva B, Senz J, Heravi-Moussavi A, Melnyk N, Salamanca C, et al. The specificity of the FOXL2 c.402C > G somatic mutation: a survey of solid tumors. PLoS One. 2009;4:e7988.
   Google Scholar
• Kim MS, Hur SY, Yoo NJ, Lee SH. Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. J Pathol. 2010;221:147–52.
   PubMed Web of Science ®Google Scholar
• D'Angelo E, Mozos A, Nakayama D, Espinosa I, Catasus L, Munoz J, et al. Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary. Mod Pathol. 2011;24:1360–7.
   PubMed Web of Science ®Google Scholar
• Kommoss S, Anglesio MS, Mackenzie R, Yang W, Senz J, Ho J, et al. FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. Mod Pathol. 2013;26:860–7.
   PubMed Web of Science ®Google Scholar
• McCluggage WG, Singh N, Kommoss S, Huntsman DG, Gilks CB. Ovarian cellular fibromas lack FOXL2 mutations: a useful diagnostic adjunct in the distinction from diffuse adult granulosa cell tumor. Am J Surg Pathol. 2013;37:1450–5.
   PubMed Web of Science ®Google Scholar
• Maillet D, Goulvent T, Rimokh R, Vacher-Lavenu MC, Pautier P, Alexandre J, et al. Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network. Gynecol Oncol. 2014;132:181–7.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.
   PubMed Web of Science ®Google Scholar
• Farkkila A, McConechy MK, Yang W, Talhouk A, Ying NG, Lum A, et al. FOXL2 402C > G mutation can be identified in the circulating tumor DNA of patients with adult-type granulosa cell tumor. J Mol Diagn. 2017;19:126–36.
   PubMed Web of Science ®Google Scholar
• Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015;7:1034–47.
   PubMed Web of Science ®Google Scholar
• Schmidt D, Ovitt CE, Anlag K, Fehsenfeld S, Gredsted L, Treier AC, et al. The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. Development. 2004;131:933–42.
   PubMed Web of Science ®Google Scholar
• Uhlenhaut NH, Jakob S, Anlag K, Eisenberger T, Sekido R, Kress J, et al. Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation. Cell. 2009;139:1130–42.
   PubMed Web of Science ®Google Scholar
• Benayoun BA, Caburet S, Dipietromaria A, Georges A, D'Haene B, Pandaranayaka PJ, et al. Functional exploration of the adult ovarian granulosa cell tumor-associated somatic FOXL2 mutation p.Cys134Trp (c.402C > G). PLoS One. 2010;5:e8789.
   Google Scholar
• Kim JH, Kim YH, Kim HM, Park HO, Ha NC, Kim TH, et al. FOXL2 posttranslational modifications mediated by GSK3β determine the growth of granulosa cell tumours. Nat Commun. 2014;5:2936.
   PubMed Web of Science ®Google Scholar
• L'Hote D, Georges A, Todeschini AL, Kim JH, Benayoun BA, Bae J, et al. Discovery of novel protein partners of the transcription factor FOXL2 provides insights into its physiopathological roles. Hum Mol Genet. 2012;21:3264–74.
   PubMed Web of Science ®Google Scholar
• Benayoun BA, Anttonen M, L'Hote D, Bailly-Bechet M, Andersson N, Heikinheimo M, et al. Adult ovarian granulosa cell tumor transcriptomics: prevalence of FOXL2 target genes misregulation gives insights into the pathogenic mechanism of the p.Cys134Trp somatic mutation. Oncogene. 2013;32:2739–46.
   PubMed Web of Science ®Google Scholar
• Benayoun BA, Georges AB, L'Hote D, Andersson N, Dipietromaria A, Todeschini AL, et al. Transcription factor FOXL2 protects granulosa cells from stress and delays cell cycle: role of its regulation by the SIRT1 deacetylase. Hum Mol Genet. 2011;20:1673–86.
   PubMed Web of Science ®Google Scholar
• Kim JH, Yoon S, Park M, Park HO, Ko JJ, Lee K, et al. Differential apoptotic activities of wild-type FOXL2 and the adult-type granulosa cell tumor-associated mutant FOXL2 (C134W). Oncogene. 2011;30:1653–63.
   PubMed Web of Science ®Google Scholar
• Rosario R, Araki H, Print CG, Shelling AN. The transcriptional targets of mutant FOXL2 in granulosa cell tumours. PLoS One. 2012;7:e46270.
   Google Scholar
• Kobel M, Gilks CB, Huntsman DG. Adult-type granulosa cell tumors and FOXL2 mutation. Cancer Res. 2009;69:9160–2.
   PubMed Web of Science ®Google Scholar
• Tran S, Lamba P, Wang Y, Bernard DJ. SMADs and FOXL2 synergistically regulate murine FSHbeta transcription via a conserved proximal promoter element. Mol Endocrinol. 2011;25:1170–83.
   PubMed Web of Science ®Google Scholar
• Blount AL, Schmidt K, Justice NJ, Vale WW, Fischer WH, Bilezikjian LM. FoxL2 and Smad3 coordinately regulate follistatin gene transcription. J Biol Chem. 2009;284:7631–45.
   PubMed Web of Science ®Google Scholar
• Park Y, Maizels ET, Feiger ZJ, Alam H, Peters CA, Woodruff TK, et al. Induction of cyclin D2 in rat granulosa cells requires FSH-dependent relief from FOXO1 repression coupled with positive signals from Smad. J Biol Chem. 2005;280:9135–48.
   PubMed Web of Science ®Google Scholar
• McTavish KJ, Nonis D, Hoang YD, Shimasaki S. Granulosa cell tumor mutant FOXL2C134W suppresses GDF-9 and activin A-induced follistatin transcription in primary granulosa cells. Mol Cell Endocrinol. 2013;372:57–64.
   PubMed Web of Science ®Google Scholar
• Laitinen MP, Anttonen M, Ketola I, Wilson DB, Ritvos O, Butzow R, et al. Transcription factors GATA-4 and GATA-6 and a GATA family cofactor, FOG-2, are expressed in human ovary and sex cord-derived ovarian tumors. J Clin Endocrinol Metab. 2000;85:3476–83.
   PubMed Web of Science ®Google Scholar
• Kyronlahti A, Vetter M, Euler R, Bielinska M, Jay PY, Anttonen M, et al. GATA4 deficiency impairs ovarian function in adult mice. Biol Reprod. 2011;84:1033–44.
   PubMed Web of Science ®Google Scholar
• Anttonen M, Parviainen H, Kyronlahti A, Bielinska M, Wilson DB, Ritvos O, et al. GATA-4 is a granulosa cell factor employed in inhibin-alpha activation by the TGF-beta pathway. J Mol Endocrinol. 2006;36:557–68.
   PubMed Web of Science ®Google Scholar
• Tremblay JJ, Viger RS. GATA factors differentially activate multiple gonadal promoters through conserved GATA regulatory elements. Endocrinology. 2001;142:977–86.
   PubMed Web of Science ®Google Scholar
• Kyronlahti A, Ramo M, Tamminen M, Unkila-Kallio L, Butzow R, Leminen A, et al. GATA-4 regulates Bcl-2 expression in ovarian granulosa cell tumors. Endocrinology. 2008;149:5635–42.
   PubMed Web of Science ®Google Scholar
• Kyronlahti A, Kauppinen M, Lind E, Unkila-Kallio L, Butzow R, Klefstrom J, et al. GATA4 protects granulosa cell tumors from TRAIL-induced apoptosis. Endocr Relat Cancer. 2010;17:709–17.
   PubMed Web of Science ®Google Scholar
• Anttonen M, Pihlajoki M, Andersson N, Georges A, L'Hote D, Vattulainen S, et al. FOXL2, GATA4, and SMAD3 co-operatively modulate gene expression, cell viability and apoptosis in ovarian granulosa cell tumor cells. PLoS One. 2014;9:e85545.
   Google Scholar
• Fuller PJ, Chu S. Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. Trends Endocrinol Metab. 2004;15:122–8.
   PubMed Web of Science ®Google Scholar
• Park M, Shin E, Won M, Kim JH, Go H, Kim HL, et al. FOXL2 interacts with steroidogenic factor-1 (SF-1) and represses SF-1-induced CYP17 transcription in granulosa cells. Mol Endocrinol. 2010;24:1024–36.
   PubMed Web of Science ®Google Scholar
• Caburet S, Georges A, L'Hote D, Todeschini AL, Benayoun BA, Veitia RA. The transcription factor FOXL2: at the crossroads of ovarian physiology and pathology. Mol Cell Endocrinol. 2012;356:55–64.
   PubMed Web of Science ®Google Scholar
• Fuller PJ, Verity K, Shen Y, Mamers P, Jobling T, Burger HG. No evidence of a role for mutations or polymorphisms of the follicle-stimulating hormone receptor in ovarian granulosa cell tumors. J Clin Endocrinol Metab. 1998;83:274–9.
   PubMed Web of Science ®Google Scholar
• Fleming NI, Knower KC, Lazarus KA, Fuller PJ, Simpson ER, Clyne CD. Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter. PLoS One. 2010;5:e14389.
   PubMed Web of Science ®Google Scholar
• Kato N, Uchigasaki S, Fukase M, Kurose A. Expression of P450 aromatase in granulosa cell tumors and sertoli-stromal cell tumors of the ovary: which cells are responsible for estrogenesis? Int J Gynecol Pathol. 2016;35:41–7.
   PubMed Web of Science ®Google Scholar
• Amsterdam A, Selvaraj N. Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes. Endocr Rev. 1997;18:435–61.
   PubMed Web of Science ®Google Scholar
• Hutton SM, Webster LR, Nielsen S, Leung Y, Stewart CJ. Immunohistochemical expression and prognostic significance of oestrogen receptor-alpha, oestrogen receptor-beta, and progesterone receptor in stage 1 adult-type granulosa cell tumour of the ovary. Pathology. 2012;44:611–6.
   PubMed Web of Science ®Google Scholar
• Francois CM, Wargnier R, Petit F, Goulvent T, Rimokh R, Treilleux I, et al. 17beta-estradiol inhibits spreading of metastatic cells from granulosa cell tumors through a non-genomic mechanism involving GPER1. Carcinogenesis. 2015;36:564--73.
   PubMed Web of Science ®Google Scholar
• Bilandzic M, Chu S, Wang Y, Tan HL, Fuller PJ, Findlay JK, et al. Betaglycan alters NFkappaB-TGFbeta2 cross talk to reduce survival of human granulosa tumor cells. Mol Endocrinol. 2013;27:466–79.
   PubMed Web of Science ®Google Scholar
• Chu S, Nishi Y, Yanase T, Nawata H, Fuller PJ. Transrepression of estrogen receptor beta signaling by nuclear factor-kappab in ovarian granulosa cells. Mol Endocrinol. 2004;18:1919–28.
   PubMed Web of Science ®Google Scholar
• van Meurs HS, van der Velden J, Buist MR, van Driel WJ, Kenter GG, van Lonkhuijzen LR. Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary. Acta Obstet Gynecol Scand. 2015;94:1269–75.
   PubMed Web of Science ®Google Scholar
• Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction. 2006;131:1–9.
   PubMed Web of Science ®Google Scholar
• Anttonen M, Ketola I, Parviainen H, Pusa AK, Heikinheimo M. FOG-2 and GATA-4 Are coexpressed in the mouse ovary and can modulate mullerian-inhibiting substance expression. Biol Reprod. 2003;68:1333–40.
   PubMed Web of Science ®Google Scholar
• Taieb J, Grynberg M, Pierre A, Arouche N, Massart P, Belville C, et al. FSH and its second messenger cAMP stimulate the transcription of human anti-mullerian hormone in cultured granulosa cells. Mol Endocrinol. 2011;25:645--55.
   PubMed Web of Science ®Google Scholar
• Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I, et al. Mullerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. Gynecol Oncol. 2008;108:141–8.
   PubMed Web of Science ®Google Scholar
• Farkkila A, Koskela S, Bryk S, Alfthan H, Butzow R, Leminen A, et al. The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors-A comparative study with inhibin B. Int J Cancer. 2015;137:1661–71.
   PubMed Web of Science ®Google Scholar
• Edson MA, Nalam RL, Clementi C, Franco HL, Demayo FJ, Lyons KM, et al. Granulosa cell-expressed BMPR1A and BMPR1B have unique functions in regulating fertility but act redundantly to suppress ovarian tumor development. Mol Endocrinol. 2010;24:1251–66.
   PubMed Web of Science ®Google Scholar
• Anttonen M, Farkkila A, Tauriala H, Kauppinen M, Maclaughlin DT, Unkila-Kallio L, et al. Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis. Lab Invest. 2011;91:1605–14.
   PubMed Web of Science ®Google Scholar
• Pepin D, Sosulski A, Zhang L, Wang D, Vathipadiekal V, Hendren K, et al. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer. Proc Natl Acad Sci USA. 2015;112:E4418–27.
   Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–76.
   PubMed Web of Science ®Google Scholar
• Farkkila A, Pihlajoki M, Tauriala H, Butzow R, Leminen A, Unkila-Kallio L, et al. Serum Vascular Endothelial Growth Factor A (VEGF) Is Elevated in Patients with Ovarian Granulosa Cell Tumor (GCT), and VEGF inhibition by bevacizumab induces apoptosis in GCT in vitro. J Clin Endocrinol Metab. 2011;96:E1973–81.
   Google Scholar
• Tsoi M, Lague MN, Boyer A, Paquet M, Nadeau ME, Boerboom D. Anti-VEGFA therapy reduces tumor growth and extends survival in a murine model of ovarian granulosa cell tumor. Transl Oncol. 2013;6:226–33.
   PubMed Web of Science ®Google Scholar
• Colombo N, Peiretti M, Garbi A, Carinelli S, Marini C, Sessa C. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23: vii20–6.
   PubMed Web of Science ®Google Scholar
• Fotopoulou C, Savvatis K, Braicu EI, Brink-Spalink V, Darb-Esfahani S, Lichtenegger W, et al. Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome. Gynecol Oncol. 2010;119:285–90.
   PubMed Web of Science ®Google Scholar
• Ertas IE, Gungorduk K, Taskin S, Akman L, Ozdemir A, Goklu R, et al. Prognostic predictors and spread patterns in adult ovarian granulosa cell tumors: a multicenter long-term follow-up study of 108 patients. Int J Clin Oncol. 2014;19:912–20.
   PubMed Web of Science ®Google Scholar
• Chua TC, Iyer NG, Soo KC. Prolonged survival following maximal cytoreductive effort for peritoneal metastases from recurrent granulosa cell tumor of the ovary. J Gynecol Oncol. 2011;22:214–7.
   PubMed Web of Science ®Google Scholar
• Pectasides D, Pectasides E, Psyrri A. Granulosa cell tumor of the ovary. Cancer Treat Rev. 2008;34:1–12.
   PubMed Web of Science ®Google Scholar
• Park JY, Jin KL, Kim DY, Kim JH, Kim YM, Kim KR, et al. Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary. Gynecol Oncol. 2012;125:80–6.
   PubMed Web of Science ®Google Scholar
• Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 1999;72:131–7.
   PubMed Web of Science ®Google Scholar
• van Meurs HS, Buist MR, Westermann AM, Sonke GS, Kenter GG, van der Velden J. Effectiveness of chemotherapy in measurable granulosa cell tumors. A retrospective study and review of literature. Int J Gynecol Cancer. 2014;24:496–505.
   PubMed Web of Science ®Google Scholar
• Brown J, Shvartsman HS, Deavers MT, Ramondetta LM, Burke TW, Munsell MF, et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol. 2005;97:489–96.
   PubMed Web of Science ®Google Scholar
• van Meurs HS, van Lonkhuijzen LR, Limpens J, van der Velden J, Buist MR. Hormone therapy in ovarian granulosa cell tumors: a systematic review. Gynecol Oncol. 2014;134:196--205.
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.
   PubMed Web of Science ®Google Scholar
• Brown J, Brady WE, Schink J, Van Le L, Leitao M, Yamada SD, et al. Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer. 2014;120:344–51.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN) [Internet]. 2012 [cited 15 May 2012]. Available from: http://www.nccn.org/.
   Google Scholar
• Geerts I, Vergote I, Neven P, Billen J. The role of inhibins B and antimüllerian hormone for diagnosis and follow-up of granulosa cell tumors . Int J Gynecol Cancer. 2009;19:847–55.
   PubMed Web of Science ®Google Scholar
• Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP, et al. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab. 1996;81:1401–5.
   PubMed Web of Science ®Google Scholar
• Mom CH, Engelen MJ, Willemse PH, Gietema JA, ten Hoor KA, de Vries EG, et al. Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort. Gynecol Oncol. 2007;105:365–72.
   PubMed Web of Science ®Google Scholar
• Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155–63.
   PubMed Web of Science ®Google Scholar
• Fleming ND, Cass I, Walsh CS, Karlan BY, Li AJ. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol. 2011;121:249–52.
   PubMed Web of Science ®Google Scholar